Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13727358 | 0.87 | LCK (0.46) | LCKSORT1CYP1A2ALDH1A1RAB9A | |
| SCHEMBL18658437 | 0.86 | ADORA3 (0.54) | ADORA3L3MBTL1ADORA2AADORA1ADORA2B | |
| SCHEMBL50044 | 0.81 | LCK (0.60) | ADORA3L3MBTL1LCKSORT1CYP1A2 | |
| SCHEMBL23089699 | 0.80 | MEN1 (0.50) | ADORA3L3MBTL1ADORA2AADORA1LCK | |
| SCHEMBL29814644 | 0.80 | MEN1 (0.50) | ADORA3L3MBTL1ADORA2AADORA1LCK | |
| SCHEMBL13727420 | 0.77 | LCK (0.44) | LCKSORT1 | |
| SCHEMBL30592890 | 0.77 | LCK (0.44) | LCKSORT1 | |
| SCHEMBL7468233 | 0.75 | S1PR2 (0.53) | ADORA3L3MBTL1ADORA2AADORA1ADORA2B | |
| SCHEMBL2975617 | 0.75 | ADORA3 (0.45) | ADORA3L3MBTL1ADORA2AADORA1ADORA2B | |
| SCHEMBL23998421 | 0.74 | PIK3CG (0.47) | ADORA3L3MBTL1ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| US-7781453-B2 | Aminopyridine-derivatives | ALTANA PHARMA AG (DE) | 2010-08-24 | — | — | US | disclosed |
| CN-100415746-C | Aminopyridine derivatives as inducible NO-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-09-03 | — | — | CN | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | ALTANA PHARMA AG | 2008-07-24 | — | — | US | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-7317021-B2 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| CN-1856493-A | Aminopyridine derivatives as inducible NO-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1670798-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | Altana Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061496-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2000021934-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043072-A1 | Aminopyridine-derivatives as inductible no-synthase inhibitors | NOS2, NOS1, NOS3 | ADORA3 251/4885L3MBTL1 3543/4885ADORA2A 351/4885 |
| US-20100280002-A1 | AMINOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | ADORA3 251/4885L3MBTL1 3543/4885ADORA2A 351/4885 |
| US-20080176894-A1 | Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine | NOS2, NOS1, NOS3 | ADORA3 680/4885L3MBTL1 3339/4885ADORA2A 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.